Ocular diseases seriously affect patients' vision and life quality, with a global morbidity of
over 43 million blindness. However, efficient drug delivery to treat ocular diseases …

Age-related macular degeneration (AMD) was described for the first time in the 1840s and is
currently the leading cause of blindness for patients over 65 years in Western Countries …

Nanotechnology has been developed rapidly in recent decades and widely applied in
ocular disease therapy. Nano-drug delivery systems overcome the bottlenecks of current …

Ophthalmic diseases can be presented as acute diseases like allergies, ocular infections,
etc., or chronic ones that can be manifested as a result of systemic disorders, like diabetes …

A drawback in the development of treatments that can reach the retina is the presence of
barriers in the eye that restrain compounds from reaching the target. Intravitreal injections …

Chronic ocular diseases can seriously impact the eyes and could potentially result in
blindness or serious vision loss. According to the most recent data from the WHO, there are …

Damage to the retinal pigment epithelium, Bruch's membrane and/or tissues underlying
macula is known to increase the risk of age-related macular degeneration (AMD). AMD is …

Background Schistosomiasis is a chronic debilitating parasitic disease accompanied with
severe mortality rates. Although praziquantel (PZQ) acts as the sole drug for the …

Age-related macular degeneration (AMD) is a major health concern in the ageing human
population. Though existing therapeutics have shown some efficacy, low retinal …

The most prevalent reason for vision impairment in aging inhabitants is age-related macular
degeneration (AMD), a posterior ocular disease with a poor understanding of the anatomic …